Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 7, 2008, Pages 783-789

  Hamadani, Mehdi ^a   Hofmeister, Craig C ^a   Jansak, Buffy ^a   Phillips, Gary ^b   Elder, Patrick ^a   Blum, William ^a   Penza, Sam ^a   Lin, Thomas S ^a   Klisovic, Rebecca ^a   Marcucci, Guido ^a   Farag, Sherif S ^c,d   Devine, Steven M ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Allogeneic; Graft versus host disease; Hematopoitic stem cell transplantation; Infliximab; Steroid refractory; Tumor necrosis factor; Unrelated donor

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; INFLIXIMAB; METHOTREXATE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; BIOPSY; CANCER MORTALITY; CANCER SURVIVAL; CANDIDEMIA; CANDIDIASIS; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DONOR SELECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; ENGRAFTMENT; FATIGUE; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HIGH RISK PATIENT; HLA TYPING; HUMAN; INCIDENCE; INFECTION RISK; INFLUENZA; INJECTION SITE REACTION; KAPLAN MEIER METHOD; KIDNEY FAILURE; LUNG ASPERGILLOSIS; LUNG FIBROSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; METASTASIS; MYCOSIS; MYELOABLATIVE CONDITIONING; NAUSEA AND VOMITING; NEUROTOXICITY; NIGHT SWEAT; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMONIA; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SEPSIS; SHORT COURSE THERAPY; SIBLING; SIDE EFFECT; STOMACH HEMORRHAGE; SURVIVAL TIME; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS INFECTION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYCOSES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44649176508     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.04.006     Document Type: Article

References (27)

1. Deeg H.J. How I treat refractory acute GVHD. Blood 109 (2007) 4119-4126
2. Ferrara J.L., Levy R., and Chao N.J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5 (1999) 347-356
3. Piguet P.F., Grau G.E., Allet B., and Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166 (1987) 1280-1289
4. Jasinski M., Wieckiewicz J., Ruggiero I., Pituch-Noworolska A., and Zembala M. Isotype-specific regulation of MHC class II gene expression in human monocytes by exogenous and endogenous tumor necrosis factor. J Clin Immunol 15 (1995) 185-193
5. Holler E., Kolb H.J., Hintermeier-Knabe R., et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25 1 Pt 2 (1993) 1234-1236
6. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
7. Knight D.M., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30 (1993) 1443-1453
8. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104 (2004) 649-654
9. Jacobsohn D.A., Hallick J., Anders V., McMillan S., Morris L., and Vogelsang G.B. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 74 (2003) 119-124
10. Yamane T., Yamamura R., Aoyama Y., et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma 44 (2003) 2095-2097
11. Hattori K., Hirano T., Miyajima H., et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91 (1998) 4051-4055
12. Devergie A., Blaise D., Attal M., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 85 (1995) 2263-2268
13. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
14. Atkinson K., Horowitz M.M., Gale R.P., Lee M.B., Rimm A.A., and Bortin M.M. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 4 (1989) 247-254
15. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
16. Bearman S.I. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85 (1995) 3005-3020
17. Copelan E., Casper J.T., Carter S.L., et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 13 (2007) 1469-1476
18. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89 (2004) 1352-1359
19. Sleight B.S., Chan K.W., Braun T.M., Serrano A., and Gilman A.L. Infliximab for GVHD therapy in children. Bone Marrow Transplant 40 (2007) 473-480
20. Holler E., Kolb H.J., Mittermuller J., et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86 (1995) 890-899
21. Caux C., Saeland S., Favre C., Duvert V., Mannoni P., and Banchereau J. Tumor necrosis factor-alpha strongly potentiates interleukin-3 and granulocyte-macrophage colony-stimulating factor-induced proliferation of human CD34+ hematopoietic progenitor cells. Blood 75 (1990) 2292-2298
22. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102 (2003) 2768-2776
23. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
24. Bruner R.J., and Farag S.S. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 30 (2003) 509-519
25. Selby L.A., Hess D., Shashidar H., de Villiers W.J., and Selby L.A. Crohn's disease, infliximab and idiopathic thrombocytopenic purpura. Inflamm Bowel Dis 10 (2004) 698-700
26. Smith C.H., Jackson K., Bashir S.J., et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 155 (2006) 160-169
27. Vidal F., Fontova R., and Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 139 (2003) W-W63